Intended for healthcare professionals

Rapid response to:

Primary Care

Coronary heart disease prevention: insights from modelling incremental cost effectiveness

BMJ 2003; 327 doi: (Published 27 November 2003) Cite this as: BMJ 2003;327:1264

Rapid Response:

We should be looking at overall mortality

Reduction of CV events and mortality is, of course, a great benefit.
However, what any patient would ask about a drug is 'Will it save my
life.' Not 'Will it make me less likely to die of a CV event, whilst at
the same time increasing my chance of dying of something else.'

I can't quite see the point of doing cost-effectiveness analysis
without taking into consideration the effect of treatment on overall
mortality. Which, in this case, was not done.

Competing interests:
None declared

Competing interests: No competing interests

04 December 2003
Malcolm E Kendrick
Medical Director Adelphi Lifelong Learning
Adelphi Lifelong Learning, Adelphi Mill Bollington SK10 5JB